Comprehensive Medical Evaluation and Assessment of Comorbidities

3.2.4.0 Sec­tion 4

On the basis of a new con­sen­sus re­port on di­a­betes and lan­guage, new text was added to guide health care pro­fes­sion­als’ use of lan­guage to com­mu­ni­cate about di­a­betes with peo­ple with di­a­betes and pro­fes­sion­al au­di­ences in an in­for­ma­tive, em­pow­er­ing, and ed­u­ca­tional style.

A new figure from the ADA-‍Eu­ro­pean As­so­ci­a­tion for the Study of Di­a­betes (EASD) con­sen­sus re­port about the di­a­betes care de­ci­sion cycle was added to em­pha­size the need for on­go­ing as­sessment and shared de­ci­sion mak­ing to achieve the goals of health care and avoid clin­i­cal in­er­tia.

A new rec­om­men­da­tion was added to ex­p­li­cit­ly call out the im­por­tance of the di­a­betes care team and to list the pro­fes­sion­als that make up the team.

The table list­ing the com­po­nents of a com­pre­hen­sive med­i­cal eval­u­a­tion was re­vised, and the sec­tion on as­sessment and plan­ning was used to cre­ate a new table (Table 4.2).

A new table was added list­ing fac­tors that in­crease risk of treat­ment-‍as­so­ci­at­ed hy­po­glycemia (Table 4.3).

A rec­om­men­da­tion was added to in­clude the 10-year atheroscle­rot­ic car­dio­vas­cu­lar dis­ease (ASCVD) risk as part of over­all risk as­sessment.

The fatty liver dis­ease sec­tion was re­vised to in­clude up­dated text and a new rec­om­men­da­tion re­gard­ing when to test for liver dis­ease.